How Long Should I Continue Maintenance Therapy?

Please Log In or Register to continue.

Release Date: April 16, 2014
Expiration Date: April 16, 2015

Expected time to complete this activity as designed: 15 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

Maintaining the response achieved with frontline therapy is an important objective in the management of multiple myeloma. The principle of continued therapy with minimal to no interruption applies to both transplantation-eligible and transplantation-ineligible patients. With the availability of novel therapies, the concept of maintenance therapy has now evolved into a standard of care and is gaining acceptance by the myeloma community, though no agent has yet been approved by the US FDA for use as maintenance therapy to treat multiple myeloma. Furthermore, while the IMWG recommends that all patients should be considered for maintenance therapy, there is not yet consensus among clinicians regarding the need for maintenance in patients who are standard risk and responded well to primary therapy, or when to continue therapy and for how long.

Target Audience

This activity is designed for physicians, pharmacists, and physician assistants who have an interest in enhancing their clinical skills in the management of patients with multiple myeloma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Summarize duration of therapy and limitations of interpretation of clinical trials for thalidomide-, lenalidomide-, and bortezomib-based maintenance therapy trials

Agenda

How Long Should I Continue Maintenance Therapy?

Instructions for Participation and Credit

This activity is eligible for credit through April 16, 2015. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates may be printed immediately after successfully completing the post-test and activity evaluation.

Contributing Author Biographies

Marie Sabo Recine, MS

Marie Recine has over 23 years experience developing technical, educational, training, and marketing materials for pharmaceutical, medical device, and biotechnology companies, and over 10 years of combined experience in the clinical and research laboratory setting. She started her career as a medical technologist and went on to receive her master of science degree in microbiology and immunology at Temple University. She continued her career first as a research associate, then senior research associate at the Liposome Company. She segued into the position of research consultant prior to starting her freelance medical writing career.

Marie and has a broad background that spans a variety of therapeutic areas, including oncology, immunology, autoimmune disease, laboratory medicine, microbiology, infectious disease, vaccines, and wound management.

Marie is a member of the American Medical Writers Association (AMWA) and was certified as a medical technologist by the American Society of Clinical Pathologists (ASCP). She recently completed the Project LEAD (Leadership Education & Advocacy Development) Institute Training Course sponsored by the National Breast Cancer Coalition.

Eugene R. Tombler, PhD, FACME

Dr. Gene Tombler has served as a medical writer, publication planner, and medical director in promotional medical communications at PharmaWrite and Excerpta Medica, an Elsevier business; and as a senior medical advisor and vice president of educational development at ArcMesa Educators. Gene has developed oncology programs for prostate, breast, ovarian, lung, liver, and kidney cancers, as well as for hematologic malignancies including AML, CML, non-Hodgkin’s lymphoma, and multiple myeloma.

Gene received his PhD in Biomedical Sciences as a Public Health Service grant trainee within the Molecular, Cellular, Biochemical and Developmental Sciences Program at the Mount Sinai School of Medicine of NYU. He served as a Research Fellow and National Research Service Award trainee in Cancer Biology and Immunopathology while he conducted preclinical and clinical breast cancer studies within the Abramson Family Cancer Research Institute at the University of Pennsylvania School of Medicine.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for .25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-14-007-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Contributing Author Disclosures

Marie Sabo Recine, contributing author, and Dr. Gene Tombler, contributing author, have disclosed no relevant financial relationships.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, has no relevant financial relationships to disclose.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is independently peer reviewed for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Ms. Recine and Dr. Tombler have indicated that they do intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Ms. Recine and Dr. Tombler have indicated that they do intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at info@managingmyeloma.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Millennium: The Takeda Oncology Company and Celgene Corporation.

©2014 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Please Log In or Register to continue.